文献速递妇科

原位成型水凝胶屏障预防宫腔镜术后宫腔粘连的多中心随机对照试验

Safety and effectiveness of an in situ-forming hydrogel barrier in preventing intrauterine adhesions after adhesiogenic hysteroscopic procedures: a multicenter, randomized, controlled trial.
PubMed 文献 · Fertil Steril · 2026-07-23

这项多中心随机对照试验纳入150例因中重度宫腔粘连行粘连分离术或FIGO 1/2型肌瘤≥1cm行肌瘤切除术的绝经前女性,按2:1随机接受原位成型宫内水凝胶屏障或无屏障。二次宫腔镜检查显示水凝胶组无粘连比例高于对照组(68.7% vs 51.4%),获益主要见于粘连分离亚组。

要点

  • 水凝胶屏障组二次宫腔镜无粘连比例68.7%,对照组51.4%。
  • 粘连分离亚组中水凝胶组无粘连比例60.3% vs 32.3%,OR 3.19(95%CI 1.29-7.90)。
  • 肌瘤切除亚组样本量有限,治疗效应估计不精确(OR 0.73,95%CI 0.15-3.62)。

核心结论

  • 在致粘连宫腔镜手术后使用原位成型宫内水凝胶屏障,可提高二次宫腔镜检查时无宫腔粘连的参与者比例。
  • 亚组分析显示获益主要局限于接受粘连分离术的参与者。

研究设计与样本

  • 多中心、随机、受试者与评估者盲法试验,在美国15个中心开展。
  • 共随机150例参与者,水凝胶屏障组99例,对照组51例,随机比例2:1。
  • 纳入年龄≥18岁、因中重度宫腔粘连行宫腔镜粘连分离术或FIGO 1/2型肌瘤≥1cm行宫腔镜肌瘤切除术、存在术后粘连风险的绝经前女性。

主要发现

  • 意向性分析中,水凝胶组二次宫腔镜无粘连比例为68.7%,对照组为51.4%。
  • 粘连分离亚组(n=102)中,水凝胶组无粘连比例60.3%,对照组32.3%,OR 3.19(95%CI 1.29-7.90)。
  • 粘连分离亚组中,水凝胶组粘连严重程度降低比例为6.3%,对照组为32.3%,OR 0.14(95%CI 0.04-0.50)。
  • 肌瘤切除亚组(n=48)中,水凝胶组粘连率16.7%,对照组21.4%,OR 0.73(95%CI 0.15-3.62)。
  • 未观察到器械相关的严重不良事件。

关键数值与推荐

  • 主要终点为盲法独立中央评审委员会通过配对视频评估的二次宫腔镜检查时无宫腔粘连的参与者比例。
  • 粘连严重程度从基线至二次宫腔镜的变化为次要终点。
  • 安全性结局包括从随机化至指数手术后3周内的器械和/或手术相关不良事件。

临床怎么用

  • 对于因中重度宫腔粘连行宫腔镜粘连分离术的患者,可考虑使用原位成型宫内水凝胶屏障以降低术后粘连风险。
  • 水凝胶屏障在位时间约为2至3周。
  • 肌瘤切除术后使用水凝胶屏障的获益尚不明确,需结合个体情况权衡。

局限性

  • 肌瘤切除亚组样本量有限,置信区间较宽,治疗效应估计不精确。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and effectiveness of an in situ-forming intrauterine hydrogel barrier compared with no barrier in preventing intrauterine adhesions after adhesiogenic hysteroscopic surgery, and to assess changes in adhesion severity in the adhesiolysis cohort. DESIGN: Randomized, multicenter, subject- and evaluator-blinded trial conducted across 15 U.S. SUBJECTS: Premenopausal women ≥18 years undergoing hysteroscopic adhesiolysis for moderate to severe intrauterine adhesions or hysteroscopic myomectomy for International Federation of Gynecology and Obstetrics (FIGO) Type 1 or 2 leiomyomas ≥1 cm, considered at risk for postoperative adhesions. INTERVENTION: After completion of the index procedure, participants were randomized 2:1 to receive an in situ-forming intrauterine hydrogel barrier (‟spacer") or no barrier. MAIN OUTCOME MEASURES: The primary endpoint was the proportion of participants without intrauterine adhesions at second-look hysteroscopy, as assessed by a blinded, independent central review committee using paired video evaluation. Change in adhesion severity from baseline to second-look hysteroscopy was a secondary endpoint. Safety outcomes included device and/or procedure-related adverse events from the time of randomization through 3 weeks after the index procedure. RESULTS: Between August 2022 and January 2025, 150 participants were randomized (hydrogel barrier: n = 99; control: n = 51). In the intention-to-treat analysis, a greater proportion of hydrogel participants were adhesion-free at second-look than controls (68.7% vs. 51.4%). In the adhesiolysis subgroup (n = 102), more participants in the hydrogel barrier arm were adhesion-free compared with controls (60.3% vs. 32.3%; odds ratio [OR] 3.19, 95% confidence interval [CI]: 1.29-7.90), and adhesion severity was reduced (6.3% vs. 32.3%; OR 0.14, 95% CI: 0.04-0.50). In the leiomyoma subgroup (n = 48), adhesion rates were 16.7% in the hydrogel group and 21.4% in controls; however, the estimated treatment effect was imprecise because of the limited subgroup sample size and wide CI (OR 0.73, 95% CI: 0.15-3.62). No serious device-related adverse events were observed. CONCLUSION: In this multicenter randomized trial, use of an in situ-forming intrauterine hydrogel barrier with a 2- to 3-week residence time after adhesiogenic hysteroscopic procedures increased the proportion of participants without intrauterine adhesions at second-look hysteroscopy compared with no intrauterine barrier. In subgroup analyses, the benefit was largely confined to participants undergoing adhesiolysis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05394662. Date of registration: 2022-05-24.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Salazar CA, Chudnoff SG, Roy KH, et al. Safety and effectiveness of an in situ-forming hydrogel barrier in preventing intrauterine adhesions after adhesiogenic hysteroscopic procedures: a multicenter, randomized, controlled trial. Fertil Steril. 2026. PMID: 42492609. doi:10.1016/j.fertnstert.2026.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。